title: In vitro investigation of self-assembled nanoparticles based on hyaluronic acid-deoxycholic acid conjugates for controlled release doxorubicin: effect of degree of substitution of deoxycholic acid.
abstract: Self-assembled nanoparticles based on a hyaluronic acid-deoxycholic acid (HD) chemical conjugate with different degree of substitution (DS) of deoxycholic acid (DOCA) were prepared. The degree of substitution (DS) was determined by titration method. The nanoparticles were loaded with doxorubicin (DOX) as the model drug. The human cervical cancer (HeLa) cell line was utilized for in vitro studies and cell cytotoxicity of DOX incorporated in the HD nanoparticles was accessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. In addition, cellular uptake of fluorescently labeled nanoparticles was also investigated. An increase in the degree of deoxycholic acid substitution reduced the size of the nanoparticles and also enhanced their drug encapsulation efficiency (EE), which increased with the increase of DS. A higher degree of deoxycholic acid substitution also lead to a lower release rate and an initial burst release of doxorubicin from the nanoparticles. In summary, the degree of substitution allows the modulation of the particle size, drug encapsulation efficiency, drug release rate, and cell uptake efficiency of the nanoparticles. The herein developed hyaluronic acid-deoxycholic acid conjugates are a good candidate for drug delivery and could potentiate therapeutic formulations for doxorubicin-mediated cancer therapy.
authors.affiliation: College of Marine Life Science, Ocean University of China, Yusan Road No. 5, Qingdao 266003, China. weiwen_1980@163.com.
authors.forename: Wen-Hao
authors.initials: WH
authors.lastname: Wei
authors.affiliation: College of Marine Life Science, Ocean University of China, Yusan Road No. 5, Qingdao 266003, China. dxm090981@163.com.
authors.forename: Xue-Meng
authors.initials: XM
authors.lastname: Dong
authors.affiliation: College of Marine Life Science, Ocean University of China, Yusan Road No. 5, Qingdao 266003, China. liucg@ouc.edu.cn.
authors.forename: Chen-Guang
authors.initials: CG
authors.lastname: Liu
mesh_terms: D045744:Cell Line, Tumor; D002626:Chemistry, Pharmaceutical / Q000379:methods; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000737:chemistry*; D003840:Deoxycholic Acid / Q000008:administration & dosage / Q000737:chemistry*; D004317:Doxorubicin / Q000008:administration & dosage / Q000737:chemistry*; D004337:Drug Carriers / Q000008:administration & dosage / Q000737:chemistry; D016503:Drug Delivery Systems / Q000379:methods; D006367:HeLa Cells; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage / Q000737:chemistry*; D053758:Nanoparticles / Q000008:administration & dosage / Q000737:chemistry*; D010316:Particle Size
chemical_list: D003692:Delayed-Action Preparations; D004337:Drug Carriers; D003840:Deoxycholic Acid; D004317:Doxorubicin; D006820:Hyaluronic Acid
references.citation: Colloids Surf B Biointerfaces. 2007 Apr 1;55(2):222-8
references.pmid: 17254755
references.citation: Colloids Surf B Biointerfaces. 2006 Jul 1;50(2):97-103
references.pmid: 16759840
references.citation: Carbohydr Res. 2009 Jan 5;344(1):98-104
references.pmid: 18950752
references.citation: Biomacromolecules. 2007 Dec;8(12):3879-85
references.pmid: 18039001
references.citation: J Anat. 1995 Oct;187 ( Pt 2):259-69
references.pmid: 7591990
references.citation: Bioconjug Chem. 2008 Jun;19(6):1319-25
references.pmid: 18481885
references.citation: Adv Drug Deliv Rev. 2008 Dec 14;60(15):1650-62
references.pmid: 18848591
references.citation: J Control Release. 2006 Mar 10;111(1-2):228-34
references.pmid: 16458988
references.citation: Colloids Surf B Biointerfaces. 2014 Jun 1;118:154-63
references.pmid: 24769392
references.citation: FEBS Lett. 1998 Dec 4;440(3):444-9
references.pmid: 9872419
references.citation: Bioconjug Chem. 2013 Apr 17;24(4):658-68
references.pmid: 23547842
references.citation: Am J Pathol. 1996 Jun;148(6):1721-6
references.pmid: 8669457
references.citation: Adv Drug Deliv Rev. 2008 Dec 14;60(15):1638-49
references.pmid: 18840488
references.citation: Biochem J. 1993 Jan 15;289 ( Pt 2):313-30
references.pmid: 8380990
references.citation: Biomaterials. 2005 Jan;26(2):125-35
references.pmid: 15207459
references.citation: Nat Rev Cancer. 2004 Jul;4(7):528-39
references.pmid: 15229478
references.citation: Biomaterials. 2010 Mar;31(8):2293-301
references.pmid: 20042234
references.citation: Cancer Chemother Pharmacol. 1990;27(1):13-9
references.pmid: 2245488
references.citation: J Immunol Methods. 1983 Dec 16;65(1-2):55-63
references.pmid: 6606682
references.citation: Matrix Biol. 2002 Jan;21(1):15-23
references.pmid: 11827788
references.citation: Biomaterials. 2012 Feb;33(4):1190-200
references.pmid: 22074664
references.citation: Int J Pharm. 2013 Aug 30;453(1):198-214
references.pmid: 22944304
references.citation: Int J Pharm. 2009 Apr 17;371(1-2):156-62
references.pmid: 19135139
references.citation: J Control Release. 2001 Jan 29;70(1-2):1-20
references.pmid: 11166403
references.citation: J Control Release. 2005 Oct 20;107(3):502-12
references.pmid: 16154659
references.citation: Methods Enzymol. 2004;387:16-33
references.pmid: 15172155
references.citation: Exp Cell Res. 1999 Nov 1;252(2):292-302
references.pmid: 10527620
references.citation: Mol Pharm. 2008 Jul-Aug;5(4):474-86
references.pmid: 18547053
references.citation: Adv Drug Deliv Rev. 2005 Feb 28;57(4):609-36
references.pmid: 15722167
references.citation: Biomaterials. 2014 Jan;35(1):550-66
references.pmid: 24135268
references.citation: J Intern Med. 1997 Jul;242(1):49-55
references.pmid: 9260566
references.citation: Pharm Res. 2002 Apr;19(4):396-402
references.pmid: 12033370
references.citation: Biomacromolecules. 2006 Dec;7(12):3336-44
references.pmid: 17154461